Schweizer Herbert P, Peacock Sharon J
Rocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
Emerg Infect Dis. 2008 Nov;14(11):1689-92. doi: 10.3201/eid1411.080431.
Genetic research into the select agents Burkholderia pseudomallei and B. mallei is currently hampered by a paucity of approved antimicrobial drug-selection markers. The strict regulations imposed on researchers in the United States but not in other parts of the world lead to discrepancies in practice, hinder distribution of genetically modified strains, and impede progress in the field. Deliberation and decisions regarding alternative selection markers (antimicrobial and nonantimicrobial drugs) by the international community, regulatory authorities, and funding agencies are needed.
对特定病原体类鼻疽伯克霍尔德菌和鼻疽伯克霍尔德菌的基因研究目前因缺乏经批准的抗菌药物选择标记而受阻。美国对研究人员实施的严格规定在世界其他地区却不存在，这导致了实践中的差异，阻碍了转基因菌株的分发，并妨碍了该领域的进展。国际社会、监管机构和资助机构需要就替代选择标记（抗菌和非抗菌药物）进行审议并做出决策。
